Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 4 sources · 17 days · First seen 28 days ago · Last updated 12 days ago

Taiwan National Health Insurance metabolic health updates

Overview

Medical experts and health authorities in Taiwan are addressing metabolic health through discussions on National Health Insurance (NHI) coverage and policy adjustments.

In mid-August, Yu Chung-jen, President of National Taiwan University Hospital, proposed including GLP-1 receptor agonists in NHI coverage to treat severe fatty liver disease. This proposal follows a shift where non-viral fatty liver disease has become a primary driver of chronic liver disease and cirrhosis in Taiwan, affecting nearly 7 million adults. The National Health Insurance Administration noted they have not yet received a formal proposal regarding these specific drugs.

By late August, the National Health Insurance Administration announced an expansion of coverage for lipid-lowering medications, effective September 1. This policy adjustment lowers the threshold for low-density lipoprotein cholesterol (LDL-C) treatment to align with clinical consensus, a move expected to benefit over 1 million patients.

Entities

National Health Insurance Administration · Ministry of Health and Welfare · National Taiwan University Hospital · Yang Pei-ming · Liver Disease Foundation

Timeline

12 days ago

[HEALTH] 3 sources
Taiwan expands health insurance coverage for lipid-lowering drugs
Taiwan is expanding National Health Insurance coverage for lipid-lowering drugs starting September 1, benefiting over 1 million patients by lowering LDL-C treatment thresholds.
28 days ago

[HEALTH] 2 sources
NTU Hospital President urges NHI coverage for GLP-1 drugs to treat fatty liver
Taiwan's NTU Hospital President urges including GLP-1 weight-loss drugs in national health insurance to treat severe fatty liver disease and prevent cirrhosis and liver cancer.

Sources

bccnews.com.tw · ctinews.com · news.cnyes.com · peoplenews.tw